Publications by authors named "Eva Laker"

Claim this Profile
E
Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa.
Deborah Ekusai-Sebatta, Ritah Shanice Namugenyi, Eva Laker, Erisa Mwaka, Rachel King

Int Health· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir-associated hyperglycemia: a narrative review.
Allan Buzibye, Barbara Castelnuovo, Robert C Bollinger, Joseph Ssebulime, Denis Omali, Eva Laker

AIDS Res Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol.
Christine Sekaggya-Wiltshire, Irene Mbabazi, Ruth Mirembe Nabisere, Lucy Alinaitwe, Brian Otaalo, Eva Agnes Odongpiny Laker

BMJ Open· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa.
Adrian Steulet, Bonniface Obura, Catriona Waitt, Eva Laker, Melanie R Nicol

Br J Clin Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.
Frank Mulindwa, Jean-Marc Schwarz, Nele Brusselaers, Martin Nabwana, Robert Bollinger, Eva Laker

Res Sq· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.
Frank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, Martin Nabwana, Robert Bollinger, Eva Laker

Res Sq· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda.
Esther Alice Nalugga, Eva Laker, Maria Sarah Nabaggala, Ahmed Ddungu, Charles Batte

BMC Nutr· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda.
Leah Mbabazi, Mariah Sarah Nabaggala, Suzanne Kiwanuka, Juliet Kiguli, Eva Laker

BMC Womens Health· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study.
Brenda Nakafeero Simbwa, Achilles Katamba, Elizabeth B Katana, Eva A O Laker, Sandra Nabatanzi

BMC Infect Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial.
Dathan Mirembe Byonanebye, Maria S Nabaggala, Agnes Bwanika Naggirinya, Mohammed Lamorde, Elizabeth Oseku, Eva Laker

JMIR Mhealth Uhealth· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
Eva Agnes Odongpiny Laker, Arnold Arinaitwe, Noela Owarwo, Annet Onzia, Benson Nasasira

Drug Saf· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B.
Caleb P Skipper, Mucunguzi Atukunda, Anna Stadelman, Nicole W Engen, Ananta S Bangdiwala, Eva Laker

Antimicrob Agents Chemother· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir-associated hyperglycaemia in patients with HIV.
Mohammed Lamorde, Martha Atwiine, Noela C Owarwo, Ahmed Ddungu, Eva O Laker

Lancet HIV· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda.
Kenneth Ssebambulidde, Ivan Segawa, Eva Laker, Mohammed Lamorde, Barbara Castelnuovo

Oxf Med Case Reports· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga, Barbara Castelnuovo

BMC Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda.
Kenneth Ssebambulidde, Ivan Segawa, Eva Laker, Mohammed Lamorde, Barbara Castelnouvo

Oxf Med Case Reports· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily.
Kay Seden, Daniel Kiiza, Eva Laker, Walter J Arinaitwe, Catriona Waitt

J Antimicrob Chemother· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala.
Eva Laker, Ivan Mambule, Damalie Nalwanga, Joseph Musaazi, Agnes Kiragga

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis